Though the authors found CD8+ lymphocytes being associated with significantly improved and FOXP3+ lymphocytes associated with significantly reduced disease‐free survival for the total number of studies included, the hazard ratio for both breast cancer outcome measures was not significant in estrogen receptor positive patients.4 The gene discussed is CD8A; the disease is breast carcinoma.